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Cigarette smoking: an important renal
risk factor - far beyond carcinogenesis
Orth SR
Division of Nephrology and Hypertension, University Hospital Berne (Inselspital), Berne, Switzerland
ABSTRACT. In recent years, it has become apparent that smoking has a negative impact on renal func-
tion, being one of the most important remediable renal risk factors. It has been clearly shown that the risk
for high-normal urinary albumin excretion and microalbuminuria is increased in smoking compared to
non-smoking subjects of the general population. Data from the Multiple Risk Factor Intervention Trial
(MRFIT) indicate that at least in males, smoking increases the risk to reach end-stage renal failure.
Smoking is particularly “nephrotoxic” in older subjects, subjects with essential hypertension and patients
with preexisting renal disease. Of interest, the magnitude of the adverse renal effect of smoking seems to
be independent of the underlying renal disease. Death-censored renal graft survival is decreased in smok-
ers, indicating that smoking also damages the renal transplant. Cessation of smoking has been show to
reduce the rate of progression of renal failure both in patients with renal disease or a renal transplant. The
mechanisms of smoking-induced renal damage are only partly understood and comprise acute hemody-
namic (e.g., increase in blood pressure and presumably intraglomerular pressure) and chronic effects (e.g.,
endothelial cell dysfunction). Renal failure per se leads to an increased cardiovascular risk. The latter is
further aggravated by smoking. Particularly survival of smokers with diabetes mellitus on hemodialysis is
abysmal. In the present review article the current state of knowledge about the renal risks of smoking is
reviewed. It is the aim of the article to point out that smoking not only increases the risk of renal cell car-
cinoma or uroepithelial cell carcinoma, but also the risk of a faster decline of renal function. The latter is
a relatively new negative aspect which has not been widely recognized.
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INTRODUCTION
The fact that smoking is a risk factor for renal and uroepithe-
lial cell carcinoma is well known. In the following, I shall
review the current knowledge about the less well known
adverse renal effects of smoking, which are of particular
importance not only for nephrologists but physicians in gener-
al. Furthermore, I shall discuss the cardiovacular complica-
tions conferred by smoking in the renal patient. 
Although earlier reports [1] had indicated that smoking
may alter renal function, it was not until 1978 that additional
information was published clearly indicating that smoking is a
renal risk factor. At that time, Christiansen [2] documented
that smoking confers an increased risk for the development of
diabetic nephropathy in patients with type 1 diabetes.
Thereafter, several studies, mostly performed by diabetolo-
gists, confirmed the finding of Christiansen even in patients
with type 2 diabetes (for review see[3, 4]). It is astonishing that
it took 19 years until nephrologists became aware that smok-
ing is a major renal risk factor. At that time the hypothesis was
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raised that smoking has a negative impact on renal function,
independent of the pre-existing renal disease [5]. Since then,
the interest into the topic and the knowledge about the
adverse renal effects of smoking has continuously increased.
Although large prospective studies are lacking, there is clear
epidemiological evidence that smoking has to be considered as
one of the most important renal risk factors. This is particu-
larly true for patients with pre-existing renal disease and eld-
erly hypertensive men, but recent evidence suggests that smok-
ing may also impair renal function in patients with apparently
normal kidneys. The epidemiological evidence for an adverse
renal effect of smoking is summarised in Table 1 and will be
discussed in detail (vide infra). Of importance in the context of
patient management, there is good evidence that smoking ces-
sation is probably the single most effective measure to retard
progression of renal failure [6].
Several potential mechanisms of smoking-induced renal
damage have been discussed [7], e.g. increase in blood pres-
sure, alteration of intrarenal hemodynamics, as well as activa-
tion of the sympathetic nerve, the renin-angiotensin and the
endothelin systems. The pathomechanisms are, however, only
partly understood. Recent evidence is available documenting
that smoking induces structural alterations of the kidney in
both humans and animal models.   
Once in end-stage renal failure (ESRF), the failure to dis-
continue smoking adversely affects the prognosis of patients
on renal replacement therapy and patients with a kidney
transplant, mainly by increasing the risk of cardiovascular
complications. Discontinuation of smoking has been shown to
be the single most effective measure to prolong life [8]. This is
particularly true in cardiovascular high risk patients such as
patients with impaired kidney function.  
EFFECT OF SMOKING ON URINARY
ALBUMIN/PROTEIN EXCRETION
IN SUBJECTS OF THE GENERAL
POPULATION WITH APPARENTLY
NORMAL KIDNEY FUNCTION
The nephrotoxic effect of smoking in the general population is
documented by a cross-sectional study in 7,476 non-diabetic
subjects in Groningen, The Netherlands [9]. The study found
that urinary albumin excretion rate correlates to the amount of
cigarettes smoked per day. After adjustment for several poten-
tial confounding factors, subjects who smoked <20 ciga-
rettes/day and subjects who smoked >20 cigarettes/day, respec-
tively, showed a dose-dependent association between smoking
and high normal albuminuria (relative risk: 1.33 and 1.98,
respectively) and microalbuminuria (relative risk: 1.92 and
2.15, respectively). Interestingly, in a study including 40,619
subjects aged 28-75 years, smoking was associated even with
increased urinary albumin concentrations far below the
microalbuminuric range [10]. Analysis of a well defined non-
diabetic and non-hypertensive subgroup of this latter study
revealed that smoking was still independently associated with
microalbuminuria [11]. Halimi et al. [12] documented a marked
risk of irreversible proteinuria that may occur despite moderate
smoking in a study including 28,409 subjects in France. These
results from the Netherlands and France have recently been
confirmed by a preliminary report documenting an association
of smoking and albuminuria in a large cross-sectional probabil-
ity sample of adults in the USA [13].
EFFECT OF SMOKING ON RENAL
FUNCTION IN SUBJECTS OF THE
GENERAL POPULATION WITH
APPARENTLY NORMAL KIDNEYS  
The question arises whether the increase in albuminuria/pro-
teinuria attributable to smoking is paralleled by an increased
risk for renal functional deterioration. 
This important issue was addressed in the study of Halimi
et al. [12]. Smokers did not exhibit lower creatinine clearance
than never smokers. Creatinine clearance was even slightly
higher in current smokers, at least in men, even when nor-
motensive and hypertensive subjects were analysed separately.
The difference was, however, small, particularly in women.
The effect of current smoking on creatinine clearance was
reversible upon smoking discontinuation. This observation is
compatible with smoking-induced early hyperfiltration. Data
from the prospective Multiple Risk Factor Intervention Trial
(MRFIT) including 332,544 men, indicate, however, that
smoking also increases the risk of ESRF in the general male
population [14]: a dose-dependent increase of the relative risk
for ESRF was found in smokers as compared to non-smokers
(up to 1.69 for heavy smokers) [15]. The increase in risk was
• Dose-dependent increase of urinary albumin excretion rate/proteinuria in cigarette smokers
• Dose-dependent increase of the risk of end-stage renal failure in male cigarette smokers of the general population
• Independent predictor of (micro)albuminuria in patients with primary hypertension
• Most powerful predictor of renal functional decline in patients with primary hypertension
• Increased risk of progression of renal failure in patients with primary renal disease
• In type 1 and type 2 diabetes mellitus: independent risk factor for the onset of microalbuminuria, for progression of microalbuminuria to manifest proteinuria 
(i.e., diabetic nephropathy) and for acceleration of the rate of progression of diabetic nephropathy to end-stage renal failure
• Increased risk of renal allograft loss
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independent of age, ethnicity, income, blood pressure, dia-
betes mellitus, prior history of myocardial infarction, or
serum-cholesterol. Unfortuantely, the data concerning the rel-
ative risk of ESRF attributable to smoking have never been
published as a full-size paper. Additional information is only
available from a retrospective case-control study analysing
data obtained from 4,142 non-diabetic participants of the
Cardiovascular Health Study Cohort, all at least 65 years of
age, who had two measurements of serum-creatinine per-
formed at least three years apart [16]. In this elderly popula-
tion the number of cigarettes smoked per day was highly asso-
ciated with an increase in serum creatinine >27 µmol/L (>0.3
mg/dL). The definition for renal functional deterioration in
this study is undoubtedly weak, but smoking may be one of the
factors explaining why an impairment of renal function is
observed in some, but not all elderly [17, 18]. This assumption
is in line with the observation in a sample of 455 adults in
Wadena, Minnesota [19], where the decrease in creatinine
clearance was greater in ex-smokers and current smokers than
in non-smokers.
It can be concluded that (i) smoking increases the risk of
albuminuria/proteinuria in the general population and (ii) that
there is some evidence indicating that smoking increases the
risk of renal functional impairment in the general population,
particularly in men and in the elderly. The definition of renal
functional deterioration in the studies available is, however,
not beyond any doubt and large prospective studies investigat-
ing hard end-points, e.g. time to doubling of serum-creatinine,
are clearly indicated. 
It is noteworthy that the negative impact of smoking on
renal function contributes to the increased cardiovascular risk
conferred by smoking. An increase in urinary albumin concen-
trations far below the microalbuminuric range is associated
with increased prevalence of established cardiovaskular risk
factors and cardiovascular morbidity in the general population
[10]. This is true even in non-diabetic and non-hypertensive
subjects [11].   
ADVERSE RENAL EFFECTS OF
SMOKING IN PATIENTS WITH
PRIMARY HYPERTENSION
Proteinuria is found in 4-18% and albuminuria in 10-25% of
patients with primary hypertension [20, 21]. Albuminuria (and
even more proteinuria) is an independent predictor of cardio-
vascular mortality in patients with primary hypertension [21-26]. 
Smoking emerged as an independent predictor of
(micro)albuminuria in several studies which examined other-
wise healthy hypertensive subjects. Mimran et al. [27] studied
lean patients with primary hypertension and found that the
prevalence of microalbuminuria was almost double in smokers
compared to non-smokers. Hörner et al. [28] confirmed this
finding and found that smoking was the strongest predictor for
albuminuria in patients with primary hypertension. The Heart
Outcomes Prevention Evaluation (HOPE)-Study [29] docu-
mented that smoking was an independent determinant of
microalbuminuria in all participants, i.e. non-diabetic and dia-
betic patients with a high cardiovascular risk profile (approxi-
mately 50% being hypertensive). Furthermore, a recent study
[30] found that patients with hypertension and left ventricular
hypertrophy smoking >20 cigarettes/d had a 1.6-fold higher
prevalence of microalbuminuria and a 3.7-fold higher preva-
lence of macroalbuminuria than never-smokers.
Important new information has become available concern-
ing the negative impact of smoking on renal functional deteri-
oration in hypertensive patients. Regalado et al. [31] per-
formed a prospective study including 51 patients with primary
hypertension for a mean follow-up of 35.5 months. Despite
reduction of mean arterial blood pressure from 126.8 ± 1.3
mmHg to 96.5 ± 1.1 mmHg, plasma-creatinine increased from
133 ± 9 µmol/L (1.5 ± 0.1 mg/dL) to 168 ± 18 µmol/L (1.9 ±
0.2 mg/dL). Factors that independently predicted renal func-
tional decline were smoking, greater initial plasma creatinine
level, and black ethnicity. Smoking was by far the most power-
ful predictor of renal functional deterioration and the only one
which is remediable. It is noteworthy that the mean increase in
plasma-creatinine for the given observation period is more
than can be expected in a representative sample of patients
with primary hypertension, so that the data of this well per-
formed, but small prospective study may not be generalisable.
Indeed, a large prospective study [32] including 5,730 black
and 6,182 non-black hypertensive male subjects (mean age
52.5 ± 10.2 years) from the Veterans Administration
Hypertension Screening and Treatment Program clinics did
not find a relation between smoking and the risk of ESRF dur-
ing a minimum of 13.9 years of follow-up. 
Thus, the issue whether or not smoking increases the rate
of progression in patients with primary hypertension remains
controversial. Considering the proven effects of smoking on
albuminuria/proteinuria it is, however, cautious to conclude
that smoking has to be considered as a renal risk factor in
hypertensive patients.   
ADVERSE RENAL EFFECTS
OF SMOKING IN PATIENTS WITH
RENAL DISEASE
The effect of smoking in patients with renal disease is of major
interest, because it can be anticipated that this population is
particularly susceptible to smoking-induced renal damage. 140 Orth SR
Diabetic nephropathy
The first well documented reports about an increased renal
risk in smokers were mostly retrospective studies in patients
with type 1 diabetes. It was noted that smokers have a higher
risk to develop diabetic nephropathy than non-smokers [2, 33]. 
In the study of Telmer et al. [33] 668 patients with type 1
diabetes were investigated. The prevalence of diabetic
nephropathy was significantly higher among “heavy” smokers
(>10 cigarettes/d for more than one year) than among “non-
heavy” smokers, i.e. 19.2% versus 12.1%. An increasing fre-
quency of nephropathy was found with increasing cigarette
consumption. Diabetic nephropathy was present in 13% of
patients who smoked <10 cigarettes/d, but in >25% in
patients who smoked 30 cigarettes/d. In a cross-sectional study
Nórden and Nyberg [34] analysed smoking habits in 47
matched pairs of patients with type 1 diabetes with and with-
out nephropathy. Patients with nephropathy had a significant-
ly higher smoking index (number of cigarettes smoked/d mul-
tiplied by number of years smoking) than control patients.
There were also significantly more current smokers (n = 22
versus n = 14), more heavy smokers (n = 20 versus n = 14),
and fewer individuals who had never smoked (n = 9 versus n
= 18) in the group with nephropathy compared to the group
without nephropathy. 
Since then, several studies confirmed an increased renal
risk in patients with both type 1 and type 2 diabetes who
smoke. 
Smoking (i) increases the risk to develop microalbumin-
uria [29, 35-45], (ii) accelerates the rate of progression from
microalbuminuria to manifest proteinuria [46-51], and (iii)
accelerates progression of renal failure [47, 52-55]. 
An association between albuminuria/proteinuria and
smoking has also been found among children with type 1 dia-
betes [40] and patients with type 1 diabetes who survived >30-
40 years [56, 57]. A genetic predisposition of smokers to devel-
op albuminuria is suggested by the results of the BErgamo
NEphrologic DIabetes Complications Trial (BENEDICT).
The DD-genotype of the ACE gene was strongly associated
with microalbuminuria in smokers [58]. 
As in non-diabetics, microalbuminuria and overt
nephropathy are independent predictors of cardiovascular
morbidity and mortality [59], adding to the increased cardio-
vascular risk conferred by smoking itself.
The magnitude of the effect of smoking on the risk to
develop microalbuminuria in patients with diabetes mellitus is
not minor. Chase et al. [35] reported that in a group of 359
young subjects with type 1 diabetes the prevalence of border-
line (>7.6 µg/min) and abnormal (>30 µg/min) urinary albu-
min excretion rate was 2.8-fold higher in smokers than non-
smokers. Similarly, the risk to have microalbuminuria short-
term after the diagnosis of type 2 diabetes is highly increased
in current smokers. The odds ratio for the presence of microal-
buminuria was 26.3 for current smoking and 3.42 for a 1%
increment in glycosylated HbA1 [44]. Although the confidence
intervalls of these latter results were wide, the data indicate
the importance of smoking compared to glycemic control as a
classic renal risk factor in diabetes mellitus. 
Concerning the risk to progress from microalbuminuria to
gross proteinuria (>300 mg/d), a prospective study with an
observation time of 4 years including 794 patients with type 2
diabetes reported a 2- to 2.5-fold higher relative risk in heavy
smokers than in never-smokers [50]. 
The acceleration of the rate of progression of renal failure
induced by smoking is dramatic. Sawicki et al. [53] calculated
the adjusted odds ratio for progression of nephropathy in
patients with type 1 diabetes. Progression was defined as an
increase in proteinuria >20% and/or a reduction of glomeru-
lar filtration rate >20% after one year of follow-up. The odds
ratio was 2.74 for each 10 cigarette pack years. In this study all
patients were on intensified insulin and antihypertensive ther-
apy, so that confounding effects of hyperglycemia and hyper-
tension are minimised. In a study of Biesenbach et al. [52] the
rate of loss of glomerular filtration rate was higher by a factor
of 1.44 and 1.66 in smoking as compared to non-smoking
patients with type 1 and type 2 diabetes, respectively. Thus, the
influence of smoking on the rate of progression is similar in
type 1 and type 2 diabetes. 
A recent prospective study with a mean follow-up time of
5.3 years including 33 patients with type 2 diabetes and mani-
fest nephropathy investigated the impact of smoking on pro-
gression of renal failure [60]. The initial serum-creatinine was
93 ± 7µmol/L (1.05 ± 0.08 mg/dL) in smokers (n = 13) and
95 ± 3 µmol/L (1.08 ± 0.03 mg/dL) in non-smokers (n = 20).
At the end of observation time, the increase of serum-creati-
nine was more pronounced in smokers as compared to non-
smokers, i.e. 157 ± 18 µmol/L (1.78 ± 0.2 mg/dL) versus 117
± 4 µmol/L (1.32 ± 0.04 mg/dL). This difference was not
explained by potential confounding factors and regression
anlaysis revealed that smoking was the only parameter that
significantly predicted renal functional decline. These data
are of particular importance, because blood pressure had
been treated according to current standards including an
ACE-inhibitor and achieving mean arterial blood pressure of
92 ± 1 mmHg. Thus, smoking seems to remain a renal risk
factor despite lowering of blood pressure to the target level
using currently recommended therapy, at least in patients
with type 2 diabetes. A confirmation of the intreguing finding
of a loss of the nephroprotective effect of ACE inhibitor-
treatment in patients with type 2 diabetes who smoke is need-
ed. Although not comparable, a retrospective case-control
study investigating patients with primary renal disease [61]
had reported that ACE inhibitor treatment counteracts theSmoking – a renal risk factor 141
deleterious effect of smoking on renal function. An explana-
tion why ACE inhibition may protect against smoking-
induced renal functional decline may be the improvement of
vascular dysfunction in smokers [62]. In vitro data suggest that
this effect is partly mediated by scavenging free radicals and
by attenuation of the cigarette-induced suppression of nitric
oxide production [63]. Due to these considerations and the
fact that despite low serum-renin, there is good evidence that
the intrarenal angiotensin II production in patients with type
2 diabetes mellitus is increased [64], the above finding of
Chuahirun et al. is contraintuitive [60].
If the data of the well performed but small study by
Chuahiran et al. can be confirmed, it can be expected that smok-
ing also counteracts the nephroprotective effect of blood pres-
sure lowering including an ACE-inhibitor in patients with type
1 diabetes. This assumption is based on the fact that the course
of diabetic nephropathy is identical in type 1 and type 2 diabetes
[65] and that the adverse renal effect of smoking on renal func-
tional decline are comparable in type 1 and type 2 diabetes [52].  
It is of major clinical importance that smokers are at
greater risk to develop type 2 diabetes [66-68]. In a prospective
cohort study on 1266 non-diabetic males aged 35-59 years
Nakanishi et al. [68] found that the relative risk to develop
impaired fasting glucose during 5 years of observation was
1.62-fold higher in ever-smokers as compared to never-smok-
ers. The relative risk to develop type 2 diabetes was dose-
dependent: 1-20 cigarettes/d = 1.88 (CI: 0.71-5.0), 21-30 ciga-
rettes/d = 3.02 (CI: 1.15-7.94), >31 cigarettes/d = 4.09 (CI:
1.62-10.29). The increased risk may be related to the fact that
smoking aggravates insulin resistance in healthy smokers, at
least according to some studies [7].
An interesting issue is the effect of smoking on the risk to
develop proliferative retinopathy. Based on a priori consider-
ations, one would expect that the risk is increased in smokers,
since damage to the microvascular bed of the kidney, i.e. dia-
betic nephropathy, is often associated with damage to the
microvascular bed of the eye, i.e. proliferative diabetic
retinopathy [69-72]. In most [33,71, 73-78] but not all studies
[41, 46, 79, 80], no difference in the prevalence of proliferative
retinopathy was found between smokers and non-smokers
with type 1 or type 2 diabetes. Vascular beds of the retina and
the kidney have a different susceptibility for smoking-induced
damage. The reasons for this difference are unknown. From
the above studies it can be concluded that if smoking has any
impact on the risk of onset and progression of diabetic
retinopathy, this effect has to be considered as minor.
In summary, there is clear evidence that smoking has
adverse effects on the onset and evolution of diabetic
nephropathy in type 1 and type 2 diabetes mellitus.
Furthermore, the number of cigarettes smoked per day and the
number of pack-years of exposure seem to be associated with
development of impaired fasting glucose and type 2 diabetes. 
Non-diabetic renal disease 
There is no evidence in the literature that smoking induces
any type of glomerulonephritis or any systemic disease involv-
ing the kidney to begin with [81-84]. Solid evidence has accu-
mulated, however, that smoking is a major renal risk factor in
patients with primary renal diseases.
In patients with autosomal dominant polycystic kidney dis-
ease (ADPKD) Chapman et al. [85] had found that individu-
als with established proteinuria had a significantly greater
pack-year smoking history than did their nonproteinuric coun-
terparts. Based on this first paper indicating an adverse renal
effect of smoking in patients with primary renal disease, we
performed a retrospective matched case-control study [61].
This European multicenter study was designed to assess
whether smoking in patients with IgA-glomerulonephritis
(IgA-GN) and ADPKD increases the risk to progress to ESRF.
Because analysis of smoking (given as pack-years; PY) showed
no strata inhomogeneity between renal diseases, IgA-GN and
ADPKD were pooled for statistical analysis. Due to small sam-
ple size and modest average tobacco consumption, the sub-
group of women was excluded from further analysis. Table 2
shows the distribution of cigarette smoking in male patients;
consumption of cigarettes was subdivided into three cate-
gories, i.e., 0-5, 5-15 and >15 PY. The crude estimators for dif-
ferent quantitative levels of smoking document a dose-
dependent increase in the risk for ESRF in male smokers as
compared to non-smokers or moderate smokers (0-5 PY)
(Table 2). After adjustment for possible confounders, multi-
variate analysis revealed that the risk for ESRF was substan-
tially higher in male smokers with no history of ACE inhibitor
treatment. In contrast, the odds ratio for ESRF of smokers
with a history of ACE inhibitor treatment was not significant-
ly increased (Table 3). Another case-control study confirmed
that male patients with glomerulonephritis who smoke are at
increased risk of renal function impairment [86]. 
Since the design of these studies was retrospective, a
prospective study would be desirable. A post-hoc analysis of a
prospective study, which had originally been performed to
evaluate the role of dyslipidemia on the progression of renal
failure in 73 patients with primary renal disease found that
smoking status at entry was related to the decline in glomeru-
lar filtration rate after 3.2 years of follow-up [87]. In patients
with chronic glomerulonephritis the loss of glomerular filtra-
tion rate was 5.3 mL/min/year in heavy smokers, but only 2.5
mL/min/year in non-smokers. Thus, smoking appears to dou-
ble the rate of progression in patients with chronic glomeru-
lonephritis. These data have to be interpreted with caution,
because the level of statistical significance was not reached.142 Orth SR
This may be due to the short observation time and the small
number of patients investigated.  
The fact that we [61] and Stengel et al. [86] did not find an
adverse effect of smoking on renal function in the small female
subgroup is presumably related to the limited sensitivity of the
studies; certainly the data do not permit to rule out an adverse
effect of smoking on renal prognosis in women. Although
speculation, it may be that females, at least prior to
menopause, are less affected by the adverse renal effect of
smoking. In favor of this hypothesis, one study including 246
patients with type 1 diabetes [88] found no relation between
smoking and diabetic nephropathy in the female population (n
= 106). In contrast, smoking males had a significantly
increased risk to develop nephropathy. A further rational is
that a recent biopsy study [89] found structural alterations of
the kidney in male but not in female smokers (vide infra). 
Only a few data are available concerning the effect of smoking
on renal function in systemic diseases involving the kidney, name-
ly lupus nephritis. A retrospective cohort study of 160 patients
with a median follow-up of 6.4 years documented that smoking at
the time of onset of lupus nephritis was an independent risk fac-
tor for more rapid progression to ESRF [90]. Life-table analysis
was performed to calculate the median time interval to ESRF. It
was 145 months in smokers and in excess of 273 months in non-
smokers. This observation seems pertinent, because the effect of
smoking was independent of hypertension and immunosuppres-
sive treatment. These data have, however, not been confirmed in
a recent prospective study including 70 consecutive patients with
lupus nephritis [91]. In this latter study, the patients were com-
pared to 70 age- and sex-matched controls with systemic lupus ery-
thematosus without evidence of nephropathy. At the last visit of
the 10 years of follow-up, 67% of lupus nephritis patients had nor-
mal plasma-creatinine, 24% had renal failure and 9% ESRF.
Hyperlipidaemia and hypertension at study onset were the only
factors associated with development of renal failure. Since no
other studies have investigated this issue, the influence of smoking
on prognosis of lupus nephritis remains unclear.
The hypothesis that heavy smoking might be a risk factor for
the development and/or progression of pauci-immune ANCA-
positive extracapillary glomerulonephritis has been forwarded
[92], but solid data on this topic are missing. Due to the damag-
ing effects of smoking on the vascular endothelium [93], it is
conceivable that smoking-induced endothelial cell death and
desquamation may predispose to the formation of antibodies
against nuclear cell antigens extruded from endothelial cells or
endothelial cell adherent polynuclear cells. Studies on this inter-
esting and clinically relevant topic are needed.
As far as systemic diseases are concerned, cigarette smok-
ing appears to be a risk factor for pulmonary complications in
two clinical situations, which are of importance for the nephrol-
ogist. First, smoking increases the risk for fatal lung disease in
hypocomplementemic urticarial vasculitis syndrome (HUVS)
[94], a rare illness related to systemic lupus erythematosus.
Second, the risk of pulmonary hemorrhage in anti-glomerular
basement membrane (GBM)-disease, i.e. for the Goodpasture
syndrome, is highly increased in smokers [95, 96].
SMOKING AND ATHEROSCLEROTIC
RENAL ARTERY STENOSIS/ISCHEMIC
NEPHROPATHY
The prevalence of atherosclerotic renal artery stenosis is
increasing in the ageing population and ischemic nephropathy is
a significant cause of ESRF in patients over 65 years of age [97].
Pack-years Cases
(n, [%])
Controls
(n, [%]) Odds ratio 95%-confidence
intervall p-value*
0-5
5-15
>15
26 [36]
17 [24]
29 [40]
47 [65]
11 [15]
14 [19]
1.0
3.5
5.8
–
1.3-9.6
2.0-17
–
0.017
0.001
Table 2. Crude smoking-associated risk of end-stagel renal failure in 144 male patients with IgA-glomerulonephritis or autosomal dominant poly-
cystic kidney disease [61]
* Wald χ2.
* Wald χ2.
Table 3. Smoking-associated risk of end-stage renal failure (stratified for ACE inhibitor treatment and adjusted for systolic blood pressure) in 144
male patients with IgA-glomerulonephritis or autosomal dominant polycystic kidney disease [61]
Pack-years Odds ratio
ACE inhibitor 
95%-confidence inter-
vall
p-value* Odds ratio
No ACE inhibitor
95%-confidence inter-
vall
p-value*
<5
>5
1.0
1.4
–
0.3-7.1
–
0.65
1.0
10.1
–
2.3-45
–
0.002Smoking – a renal risk factor 143
The incidence of renal vascular stenosis increases as the
extent of peripheral vascular disease increases [98]. Since the
latter is common in smokers, it is not surprising that smokers
have a higher risk of critical atherosclerotic renal artery steno-
sis [99]. Smoking is well known to promote atherogenesis. It is
of interest that plasma total homocysteine concentration, a
predictor of atherogenic risk, is strongly and dose-dependent-
ly related to cigarette smoking [100, 101]. There is, however,
no doubt that other pathogenic mechanisms also play a role. 
Hadj-Abdelkader et al. [102] examined elderly hyperten-
sive patients with renal failure by arteriography. A significant-
ly higher proportion of patients with atherosclerotic renal
artery stenosis, i.e. 80.5% were smokers compared to patients
without atherosclerotic renal artery stenosis, i.e. 44%. A cor-
relation was found with the number of cigarettes smoked and
the exposure time. In a Spanish observational multicenter
study 156 elderly patients with bilateral atherosclerotic renal
artery stenosis and elevated serum-creatinine concentration
were investigated. A high proportion, i.e. 70% were smokers
[103]. As one would expect, the prevalence of smokers is
increased both amongst patients with unilateral [104] and
bilateral [105] atherosclerotic renal artery stenosis. 
Although no reports are available about the rate of pro-
gression of renal failure in smokers versus non-smokers with
renal artery stenosis/ischemic nephropathy, it is likely that
smoking accelerates the course of renal failure. This assump-
tion is based on the consideration that besides progressive nar-
rowing of the renal artery, a combination of hypertensive and
atheroembolic damage (i.e., cholesetrol embolism), is likely to
contribute to progressive loss of renal function in patients with
so-called ischemic nephropathy. Actually, smoking is a risk
factor for cholesterol embolism [106-108]. 
In a group of 89 normotensive, non-diabetic elderly sub-
jects with different degrees of peripheral atherosclerosis and
no clinical signs of ischemic nephropathy, renovascular hyper-
tension or other nephropathies, evaluation of renal function
and plasma flow revealed that despite normal values for
glomerular filtration rate, renal plasma flow declined progres-
sively in parallel with the severity of peripheral atherosclerosis
[109]. Stepwise multiple regression showed that the decrease
in renal plasma flow was best explained by smoking and LDL-
cholesterol [109]. Since there was a close association between
the severity of extrarenal atherosclerosis and renal hypoperfu-
sion, the authors concluded that the existence of initial
ischemic nephropathy may be present in these subjects. These
findings implicate that renal function should be assessed in
patients with extrarenal atherosclerosis, particularly in those
with classic cardiovascular risk factors. 
ADVERSE EFFECTS OF SMOKING
IN PATIENTS ON RENAL
REPLACEMENT THERAPY
Lower serum albumin concentrations predict increased mor-
tality in hemodialysis patients. According to Wave-1 of the
United States Renal Data System Dialysis Morbidity and
Mortality special study, baseline serum albumin is significant-
ly lower in active smokers as compared to non-smokers on
hemodialysis [110]. It is of note that smoking is a highly signif-
icant risk factor of death during the first 90 days on hemodial-
ysis [111]. Conversely, the prevalence of active smokers among
long-term survivors on hemodialysis is low (11.8%) [112].
The analysis of 936 hemodialysis patients enrolled in the
baseline phase of the Hemodialysis Study sponsored by the 
US National Institutes of Health revealed that diabetes and
smoking are strongly associated with cardiovascular disease
[113]. In a national random sample of new ESRD in the USA
(n = 4,025), coronary artery disease was present in 38% of
patients [114]. Of the total cohort, 17% had a history of
myocardial infarction and 23% had angina. Several conven-
tional risk factors, including advancing age, male gender, dia-
betes mellitus, and smoking, were significantly associated with
coronary artery disease. Bypass surgery compared to angio-
plasty yields better results in patients with ESRF. In this con-
text, it is of importance to be aware of the fact that smoking
results in a very poor outcome after bypass surgery. One ret-
rospective study investigating 44 dialysis patients undergoing
coronary artery bypass grafting from 1984 to 1997 reported a
five-year survival of 0% for smokers and 83.6% ± 7.6% for
non-smokers [115].
Smoking further adds to the increased mortality in patients
with diabetes mellitus on hemodialysis, being an independent
risk factor contributing particularly to cardiovascular death
[47, 49, 116, 117]. In one study, smoking and increasing age in
patients with diabetes mellitus were the most important
adverse features for outcome at the start of renal replacement
therapy [118]. The relative risk for mortality in current ciga-
rette smokers in this latter study was 2.28.  
In dialysed patients with type 1 diabetes smoking has been
shown to confer a relative risk for lethal myocardial infarction
of 2.6 [119]. In a group of diabetic patients on hemodialysis (n
= 22 smokers and n = 30 non-smokers), most of them having
type 2 diabetes, the 5-year survival rate of the smoking patients
was significantly decreased, i.e. 9% versus 37% in the non-
smoking subjects. Cigarette smokers had higher fibrinogen
and systolic blood pressure values. At the endpoint of the
study, the incidence of myocardial infarction was significantly
higher in the smoking patients (77% versus 13%).
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in both patient groups, but were more frequent in smokers
(80% versus 63%) [120].
Smoking also confers a higher risk for atherosclerotic
lesions outside the heart. In a study including 89 patients on
hemodialysis and 30 on chronic ambulatory peritoneal dialysis,
smoking correlated with the mean internal diameter of carotid
arteries, the degree of carotid stenosis and the number of
plaques in the carotid arteries [121]. An analysis of data from
waves 1, 3 and 4 from the United States Renal Data System
Dialysis Morbidity and Mortality Study documented that
smoking is independently associated with peripheral vascular
disease in hemodialysed patients (odds ratio up to 1.55) [122]. 
The risk of atrial fibrillation, a frequent arrythmia in
hemodialysis patients, appears to be associated to coronary
heart disease and may contribute to cardiovascular morbidity
and mortality in ESRF [123]. Smoking per se does, however,
not seem to be of importance for ventricular premature beats
or complex ventricular arrhythmia in hemodialysis patients
[124, 125]. Of interest, smoking contributes, at least partly, to
the decreased heart rate variability observed in patients with
ESRF [126]. Furthermore, it is a risk factor for systolic dys-
function in dialysis patients [127]. As far as left ventricular
function is concerned, a study including 217 non-diabetic dial-
ysis and transplant patients revealed that besides high alkaline
phosphatase (suggestive of hyperparathyroidism) and high
serum creatinine levels (reflecting degree of uremia), smoking
was the most significant and independent variable associated
with low-output left ventricular failure [128].
According to a study from the U.S.A., which investigated a
cohort of 1,572 patients (mean age 57.4 ± 15.0 years) who
started hemodialysis in 1989, smoking is amongst the strongest
predictors of the number of hospital days per year [129]. The
major part of these patients were African Americans (63.7%)
and 33% had diabetes mellitus as the primary cause of ESRF.
Apart from cardiovascular and pulmonary complications, the
increased number of hospital days per year in smokers on
hemodialysis is probably also due to the the increased risk of
early and late fistula failure [130].
Concerning patients on continuous peritoneal dialysis,
only a few scattered informations about the adverse effects of
smoking are available. Of importance, smoking increases the
risk of permanent change to hemodialysis due to complica-
tions [131]. For non-diabetic patients, age, on treatment serum
albumin, and current smoking were significant survival risk
factors [132]. Whether smoking is a significant risk factor for
the development of peripheral vascular disease in these
patients, is controversial [133, 134], although there is no plau-
sible reason why it should not be.
In the context of management of the patient on renal
replacement therapy, it is of importance that smoking is asso-
ciated with incompliance in hemodialysis and peritoneal dialy-
sis patients [135]. 
ADVERSE EFFECTS OF SMOKING
IN PATIENTS WITH A RENAL
TRANSPLANT
Contraintuitively, it has been documented that smoking does
not appear to increase the risk of microalbuminuria in patients
with a renal transplant [136]. Most studies published to date
indicated a lack of correlation of smoking with the develop-
ment of progressive allograft dysfunction [137, 138]. 
A recent cohort study of 645 adult renal allograft recipients
performed from 1985 to 1995 evaluated the relationship
between smoking and graft outcome [139]. Twenty-four per-
cent of recipients (156/645) were smokers at the time of trans-
plant evaluation. Of these, 90% continued to smoke after
transplantation! Pretransplant smoking was significantly asso-
ciated with reduced overall graft and death-censored graft sur-
vival. Patients who were smokers at the time of pretransplant
evaluation had kidney graft survival of 84%, 65%, and 48% at
1, 5, and 10 years, respectively, compared with graft survival in
non-smokers of 88%, 78%, and 62% (p = 0.007).
Pretransplant smoking adversely affected death-censored graft
survival in recipients of cadaveric (p = 0.02) and of living
donor kidneys (p = 0.02). Reduced graft survival in pretrans-
plant smokers could not be accounted for by differences in
rejection episodes (64% versus 61%). In a multivariate analy-
sis, pretransplant smoking was associated with a relative risk of
2.3 for graft loss. Among patients with a smoking history
before transplantation, death-censored graft survival was sig-
nificantly higher for those who quit smoking before transplant
evaluation. Thus, this study documents that cigarette smoking
before kidney transplantation contributes significantly to allo-
graft loss, an effect that is not explained by increases in rejec-
tion episode or patient death. The finding that smoking cessa-
tion before renal transplantation has beneficial effects on graft
survival is of major importance for the management of
patients with ESRF who are considered for renal transplanta-
tion. In a retrospective analysis, current smoking has also been
documented to be a risk factors for decreased graft survival in
first-time kidney transplant recipients aged ≥60 years [140].
In an ongoing prospective study using the large
Collaborative Transplant Study database, the issue is currently
adressed by G Opelz (Heidelberg, Germany). A preliminary
retrospective analysis of Opelz suggests that smoking by itself
adversely affects late graft function, even if corrections are
made for cardiovascular death with a functioning graft (per-
sonal communication). A similar analysis was performed by
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likely that the final results of these investigations will confirm
the data of Sung et al. [139]. 
The effect of smoking on renal allograft function may
depend on the renal disease that has led to ESRF. In patients
who had reached ESRF as a result of lupus nephritis, the risk
of renal transplant loss was substantially increased in smokers
[142]. In this study, smoking demonstrated both the strongest
association and the highest relative risk for allograft loss (rel-
ative risk 2.5, p < 0.0001) as compared to the other factors
which confered an increased risk for allograft loss, i.e., delayed
graft function, acute rejection episodes, and total HLA mis-
matches. Lupus nephritis accounts only for a small proportion
of patients requiring renal transplants, but the above results
are of major clinical importance and point to the possibility
that the alterations of the immune response reported in smok-
ers [5] may be particularly detrimental in patients with
immunoregulatory abnormalities such as systemic lupus ery-
thematosus.
It is of note that an investigation of kidney donor lifestyle
factors, including smoking, drinking, drug use, and sexual his-
tory, found no significant negative impact on renal allograft
survival [143].
The evidence that the risk of death with a functioning graft
is increased in patients with a history of cigarette smoking is
beyond any doubt. The magnitude of the negative impact of
smoking in renal transplant recipients is quantitatively similar
to that of diabetes mellitus [144]. A retrospective analysis [145]
found a higher rate of cardiovascular death with a functioning
graft. This has also been documented in first-time kidney
transplant recipients aged ≥60 years [140]. Compared to never-
or ex-smokers, the diabetic renal transplant recipient had a
significantly increased risk of early death if he smoked during
the predialysis phase or after having received his graft [49]. 
The increase in cardiovascular death is due to the well
known atherogenic effects of smoking [146, 147]. Smoking
appears to increase the risk for low-output left ventricular fail-
ure in patients with a renal transplant [128]. As one would
expect, cigarette smoking at the time of transplantation is an
independent risk factor for cerebrovascular and peripheral
vascular disease in transplanted patients [148]. Smoking post-
transplantation is a risk factor for carotid plaques [149] and
peripheral vascular occlusive disease [150]. 
Diabetic transplant recipients are at a high risk for foot
pathology leading to amputation. Smoking has a profoundly
negative effect on the amputation rate as has an amputation
prior to transplantation [151].
Another clinically relevant aspect is the higher incidence of
cancer in smokers. In one study, cigarette smoking was associ-
ated with an increased risk for cancer, with each 10 pack-years
smoked at transplant increasing the risk by 1.12 (1.02-1.21; p =
0.016) [152]. It has also been reported that smoking increases
the risk for squamous cell carcinoma of the skin [153].
Furthermore, exposure to the sun and smoking are risk factors
for dysplastic and malignant lip lesions in renal transplant
recipients [154].
Finally, smoking increases the risk for osteoporosis in cor-
ticosteroid-treated transplant patients (and patients with
chronic glomerulonephritis) [155] and favours the develop-
ment of post-transplant erythrocytosis [156]. 
POTENTIAL MECHANISMS OF
SMOKING-INDUCED RENAL DAMAGE
Several potential mechanisms of smoking-induced renal dam-
age have been discussed in detail elsewhere [7] and are sum-
marised in Table 4. These include acute effects, particularly
sympathetic activation (influencing blood pressure and renal
hemodynamics), and chronic effects, particularly endothelial
cell dysfunction (diminished nitric oxide availability, dimin-
ished endothelial cell-dependent vasodilation, and intimal cell
hyperplasia). The precise nature of the nephrotoxic effect of
smoking is, however, far from being understood. It will be par-
ticularly difficult, probably impossible, to delineate which sub-
• Increased sympathetic nerve activity
• Increase of blood pressure and heart rate
• Decreased fall of night-time blood pressure
• Increase of renal vascular resistance leading to a decrease in glomerular filtration rate and renal plasma flow
• Increase of intraglomerular capillary pressure
• Aggravation of hyperfiltration in patients with diabetic nephropathy 
• Atherosclerosis of renal arteries and myointimal hyperplasia of the intrarenal arteries and arterioles
• Endothelin-1- and/or angiotensin II-mediated proliferation and matrix accumulation of vascular smooth muscle cells, endothelial cells and mesangial cells
• Tubulotoxic effects with alteration of tubular function
• Toxic effects on endothelial cells
• Oxidative stress
• Increased clotting of platelets
• Impaired lipoprotein and glycosaminoglycan metabolism
• Modulation of the immune response
• Vasopressin-mediated antidiuresis
• Insulin resistance
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stance(s) in tobacco smoke is (are) responsible for the adverse
renal effects of smoking. 
Some pathomechanisms of smoking-induced renal dam-
age, which seem of particular importance, are briefly discussed
in the following.
Increase in sympathetic activity and blood pressure 
Since the first decade of the 20th century it has been
known that smoking induces a transient increase of BP and
heart rate [157]. The increase in BP and heart rate seems to be
related to nicotine per se, since no such changes occur when
nicotine-free cigarettes are smoked [158]. Today we know that
these acute hemodynamic effects are mediated mainly via sym-
pathetic activation and vasopressin release. In addition, in
patients with primary hypertension an increase in cortisol,
adrenocorticotrophic hormone (ACTH) and plasma aldos-
terone concentration has been noted during smoking [7]. 
Grassi et al. [159] demonstrated that nicotine increases
sympathetic activity via direct stimulation of postganglionic
sympathetic nerve endings: smoking a single cigarette marked-
ly increased plasma concentrations of norepinephrine and epi-
nephrine in healthy volunteers, whereas postganglionic muscle
sympathetic nerve traffic decreased significantly. Thus, nico-
tine directly stimulates catecholamine release from peripheral
sympathetic nerve endings and the adrenal medulla [160].
Increased sympathetic activity may also accelerate progression
of renal failure [161]. Thus, it is plausible to assume that a fur-
ther increase of catecholamine release from peripheral sympa-
thetic nerve endings induced by smoking in subjects with renal
disease may damage the kidney via two mechanisms, i.e., indi-
rectly through blood pressure elevation, but also as a direct
result of activation of the sympathetic system.
In view of the importance of blood pressure on the evolu-
tion of renal disease, the effects of smoking on blood pressure
are of considerable interest. Ambulatory BP measurements
documented that smoking in parallel with the stimulation of
the sympathetic system causes a significant, but transient
increase (lasting ~30 minutes) of blood pressure in healthy
[162] and hypertensive subjects [163, 164]. This was also found
in patients with type 1 [165, 166] and type 2 diabetes [167] or
primary renal disease [168]. 
Smoking also seems to alter the diurnal rhythm of blood
pressure. Hansen et al. [169] reported that the night/day ratio
of systolic and diastolic blood pressure in healthy smokers was
lower than in non-smokers. In one study a derangement of the
diurnal rhythm of blood pressure was not found in patients
with type 1 diabetes who smoked. In contrast, a preliminary
communication [170] documented decreased ratios of daytime
to nighttime blood pressure in both smoking healthy volun-
teers and in subjects with type 1 diabetes. It is probable that
the presence or absence of autonomic neuropathy in patients
with diabetes mellitus is responsible for these contrasting
results. For instance, in patients with type 1 diabetes smoking
increases systolic blood pressure only in subjects without auto-
nomic neuropathy [166]. 
Alteration of intrarenal hemodynamics
Ritz et al. [168] performed a study in healthy volunteers
with a history of limited cigarette consumption (<10 ciga-
rettes/d) to investigate the effects of smoking on the healthy
kidney: smoking (as compared to sham-smoking) caused a sig-
nificant decrease in glomerular filtration rate (GFR), filtration
fraction (FF) and renal plasma flow (RPF) as measured by
radioisotope infusion clearance. Renovascular resistance
increased significantly. The FF is a surrogate marker of
glomerular capillary pressure. This parameter decreased in
healthy volunteers. At first sight this observation may appear
paradoxical, since reduced intraglomerular pressure should
provide nephroprotection, but the renal response is apparent-
ly different in subjects with and without renal disease. The
findings of Ritz et al. concerning GFR and RPF were con-
firmed by Halimi et al. [171] in non-smokers who chewed a
nicotine chewing gum. Interestingly, in this letter study renal
vasoconstriction did not occur in smokers. The authors con-
cluded that smokers continue to exhibit the systemic response
to nicotine, i.e., an increase in blood pressure and heart rate,
but are tolerant to the renal effects of nicotine. The latter was
attributed to a compensatory increase of the synthesis of cyclic
guanosine monophosphate (cGMP) in the kidney of smokers
as indicated by increased urinary excretion. In a cross-section-
al study in 30 subjects with no known vascular risk factors
other than chronic cigarette smoking and 24 age- and sex-
matched non-smokers without any vascular risk factors,
Gambaro et al. [172] reported that smokers had a significant
reduction of RPF, but normal GFR. Thus, there is no doubt
that acute and chronic smoking induces renal functional alter-
ations, which differ slightly according to the experimental set-
ting.  
Ritz et al. [168] also compared the renal hemodynamic
effects of smoking in volunteers with those in patients with
IgA-glomerulonephritis. Whilst the increase in mean arterial
pressure and heart rate was similar in patients with IgA-
glomerulonephritis and volunteers, a significant decrease in
GFR and FF was not demonstrable in patients with IgA-
glomerulonephritis, in contrast to what was seen in volunteers.
During smoking, a significant increase in the urinary albu-
min/creatinine ratio was noted, further pointing to an adverse
effect of smoking on glomerular capillary pressure.
Taken together these findings are consistent with the
hypothesis that in patients with glomerular disease, in whom
the preglomerular vasculature is presumably vasodilated,
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vasodilation. As a result one would expect that the increase in
systemic pressure is transmitted partially to the glomerular
microcirculation, causing acute glomerular hypertension. As
reported by Benck et al. [173] pretreatment with the α-adren-
ergic blocker prazosin (compared to placebo) failed to affect
the change in renal hemodynamics, whilst pretreatment with
the ß-blocker atenolol obliterated the renal hemodynamic
response. This finding together with the observation of an
abrogation of the adverse renal effect of smoking by ACE
inhibitor treatment in patients with primary renal disease [61]
is consistent with the hypothesis depicted in Figure 1.
Oxidative stress 
Oxidative stress is probably another major player in the
genesis of smoking-induced vascular renal injury. Extrusion of
glutathione from endothelial cells and activation of the hexose
monophosphate shunt, which is necessary to maintain glu-
tathione in the reduced state, point to the presence of oxida-
tive stress, which may be imposed by the free radicals that are
present in tobacco smoke [174]. The concentrations of antiox-
idant enzymes such as glutathione peroxidase, catalase and
superoxide dismutase decrease and markers of oxidative stress
increase as renal insufficiency advances [175]. The patient with
renal failure may thus be particularly susceptible to additional
oxidative stress induced by smoking.  
Smoking-induced nitric oxide depletion
The inhibitory effect of smoking on nitric oxide generation
may play a critical role in increasing renal vasculature tone. In
addition, intrarenal arterial dilation in response to nitroglycer-
ine is significantly impaired in type 2 diabetic patients who
smoke [176]. Nitric oxide depletion in smokers may also pro-
mote smooth vascular cell and mesangial cell proliferation
[177, 178]. A genetic approach to explain the different suscep-
tibility of individuals to smoking-induced organ damage has
been proposed by Wang et al. [179]: the risk of atherogenesis
appears to be excessively high in patients who are homozygous
for the endothelial nitric oxide synthase 4a (ecNOS4a) gene.
This genotype predisposes to endothelial dysfunction and is
associated with an increased coronary risk in smokers.
Whether a similar genetic susceptibility determines an
increased renal risk in smokers is an issue that deserves further
investigation.  
PATHOHISTOLOGICAL FEATURES OF
SMOKING-INDUCED RENAL DAMAGE
An increase in thickness of walls of arterioles of organs not in
direct contact with cigarette smoke, mainly due to fibroelastic
intimal proliferation and hyaline thickening in the intima, has
been observed in various organs of individuals without renal
disease [180, 181], including the kidney [182-184].
In a renal biopsy study, the histological findings of 107
patients (aged 48 ± 12 years) with chronic renal failure were
assessed by investigating the effect of smoking on glomeru-
losclerosis and vascular damage [89]. Most of these patients
were suffering from glomerular disease with marked protein-
uria, only a minority had been treated with an ACE inhibitor
at the time of biopsy and blood pressure was not well con-
trolled (152/91 mmHg). Smoking was not associated with
glomerulosclerosis. As compared to non-smokers, ever-smok-
ers exhibited more severe myointimal hyperplasia. This finding
was particularly evident in patients over 50 years of age. In
younger patients, a trend toward arteriolar changes was evi-
dent for smoking, but it did not reach statistical significance. In
females, no correlation was observed. This may due to the fact
that women were less likely to be smokers and smoked less
than half as many pack-years than did men. 
The above study is important, because it documents that
ever-smoking increases myointimal hyperplasia in elderly male
patients with renal disease. Since hypertension per se seems
not to be related to myointimal hyperplasia of intrarenal arte-
rioles [185], the effect of smoking has to be considered as par-
ticularly important. The negative finding concerning glomeru-
losclerosis does not exclude a negative effect of smoking on
glomerular structure. Using a more precise method for quan-
tification of renal damage, our group found more severe
glomerulosclerosis and tubulointerstitial fibrosis in a rat model
of focal-segmental glomerulosclerosis, i.e. the subtotally
nephrectomised rat [186]. Whether this is true for humans
with non-inflammatory renal disease as well remains to be
determined. An increase in glomerular basement width in
patients with type 2 diabetes who smoke has been reported in
a preliminary study [187]. A rare form of glomerulosclerosis,
i.e. idiopathic nodular glomerulosclerosis, has been reported
to be observed almost exclusively in smokers. In this latter
renal biopsy study including 5,073 patients, 23 cases of idio-
pathic nodular glomerulosclerosis were diagnosed. Ninety-one
percent of these cases were heavy smokers (52.9+6.9 pack
years) and 96% had hypertension. Seventeen of the patients
Figure 1. Hypothetical sequence of smoking-induced activation of the
renin-angiotensin system via activation of the sympathetic nervous sys-
tem as one major pathomechanism of smoking-induced renal damage. 148 Orth SR
were followed-up and 6 reached ESRF after a mean of 8.7
months. Importantly, cessation of smoking significantly
improved renal prognosis.
REVERSIBILITY OF SMOKING-
INDUCED RENAL DAMAGE
The above observation in patients with idiopathic nodular
glomerulosclerosis or a renal transplant indicate that cessation
of smoking may substantially reduce the rate of progression of
renal failure. The question arises whether this is also true in
patients with common renal diseases. 
One study in patients with type 1 diabetes and nephropa-
thy provided convincing evidence in this respect [35]: in
patients with adequate control of blood pressure, cessation of
smoking significantly decreased urinary albumin excretion,
although glycemia was not perfectly controlled. In another
study, progression was found in 53% of current smokers, 33%
of ex-smokers and 11% of non-smokers [53].
It is plausible to assume that this may also be true in non-
diabetic renal disease. Pinto-Sietsma et al. [9] found that the
risk of microalbuminuria in non-diabetic subjects is only minor
in ex-smokers, but not in current smokers. There is some evi-
dence, however, that smoking-induced decrease in renal plas-
ma flow is not completely reversible after smoking cessation
[172]. 
The present data do not allow to draw a definite conclusion
about the magnitude of the renal benefit derived from smok-
ing cessation. There is, however, good evidence indicating that
smoking cessation is one of the single most effective measures
to retard progression of renal failure.  
CONCLUSION
Smoking is one of the most important remediable renal risk
factors. It has a negative impact on renal function even in sub-
jects without apparent renal disease, but the adverse renal
effects of smoking are particularly eminent in patients with a
diseased kidney. Importantly, the increase in the rate of pro-
gression of renal failure attributable to smoking seems to be
independent of the underlying renal disease. 
Nephrologists have to be aware of two major growing med-
ical problems. First, the increase in the number of patients
requiring renal replacement therapy, which is partly due to cig-
arette smoking. Second, the dramatic increase of deaths relat-
ed to cigarette smoking. The World Health Organization esti-
mated that world-wide tobacco abuse accounted for 3 million
deaths in 1996 and even 10 million deaths are expected for the
year 2020 [189]. 
Besides improvement of renal prognosis, cessation of
smoking undoubtedly improves cardiovascular prognosis in
the renal patient [6]. Thus, Even if ESRF is reached, smoking
should be discontinued. Smoking is the strongest predictor of
mortality in type 2 diabetes [6], the fastest growing population
reaching ESRF. According to lifetable analyses, smoking ces-
sation prolongs the life of a 45-year-old smoking, hypertensive,
diabetic male by 4-5 years; the treatment of hypertension is
estimated to prolong the life of the same individual by only 1
year [190]. Of note, even among people who have a history of
heavy smoking, the risk of coronary events can be halved by
stopping the habit. This benefit from cessation of smoking is
seen regardless of how long or how much a person has previ-
ously smoked [191]. It has been stated that “persuading hyper-
tensive patients not to smoke is the single most effective meas-
ure we can take to reduce their risk” [192]. According to esi-
mates the risk of myocardial infarction can be reduced by 50-
70% as a consequence of cessation of smoking. In contrast, the
treatment of hypertension results in a reduction of risk of
myocardial infarction of “only” 2-3% for each 1 mmHg decline
in diastolic BP [193].
Tobacco control programs with the ultimate goal to reduce
tobacco use by young individuals are effective [194]. Besides
such important preventive measures, major efforts have to be
undertaken to help patients to quit smoking. These include the
most effective pharmaceutical smoking cessation approaches
known to date, i.e. therapy with sustained-release bupropion
and nicotine replacement therapy [195, 196].  
Management of the renal patient requires information
about (i) the magnitude of the renal and cardiovascular risk
related to smoking including the benefits from smoking cessa-
tion and (ii) application of the above modern therapeutic
modalities to increase the success rate in patients willing to
stop smoking. To the best of my knowledge, there is no infor-
mation about the exact pharmacokinetics of sustained-release
bupropion in patients with impaired renal function.
Apparently, bupropion does not accumulate in renal failure.
In contrast, nicotine accumulates in renal failure [197], a fact
which has to be acknowledged when treating patients with
nicotine replacement therapy. Accumulation of nicotine may
limit the success rate of smoking discontinuation in patients
with renal failure, because the patient is used to a higher level
of "intoxication". Actually, diabetic patients with nephropathy
have smoked more and still smoke more than patients without
nephropathy [48]. On the other hand, it is plausible to assume
that more renal patients than individuals in the general popu-
lation will stop smoking, because they are afraid of the
prospect to progress to ESRF. This assumption of greater
compliance in severely ill patients is based on the observation
that in subjects receiving intervention to stop smoking one
year smoking cessation rate is approximately 35% in healthy
subjects [195] but approximately 70% in patients after a
myocardial infarction [198]. It has to be pointed out that toSmoking – a renal risk factor 149
date, no data are available about the success of a modern
smoking cessation strategy in renal patients.    
ACKNOWLEDGMENT 
This paper is dedicated to Prof. Ed Nelson, first President of the
PTID Society and Editor-in-Chief of Tobacco Induced Diseases,
who kindly invited me to write this article and sadly passed away
recently.
The data given in Tables 2 and 3 are reprinted by permission of
Blackwell Publishing, Inc.
NOTE ADDED IN PROOF
As discussed on page 142, males may be more susceptible to
smoking-induced renal damage than females. Recent data
strengthen this hypothesis [199]: A population-based, cross-
sectional study [200] of 11,247 Australian adults revealed that
smoking was independently associated with renal impairment
in men with an odds ratio of 3.59, but not in women. Smoking
was significantly associated with proteinuria in subjects with
high-normal systolic blood pressure, with odds ratios ranging
from 3.64 at 131.5 mm Hg to 5.76 at 139.5 mm Hg, and in sub-
jects with high-normal 2-hour glucose levels, with odds ratios
ranging from 1.76 at 7.0 mmol/L to 10.84 at 7.7 mmol/L.
Lifetime exposure, but not current level of smoking, correlat-
ed with lower estimated glomerular filtration rate and greater
urine protein-creatinine ratio. Tozawa et al. [201] investigated
a large Japanese population (n = 5,403) and found that smok-
ing conferred a relative risk of 1.28 for developing proteinuria
in men, but it did not increase the risk in women.
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